BR112018002342A2 - polímeros furtivos intrinsecamente desordenados e geneticamente modificados para entrega e métodos para uso dos mesmos - Google Patents

polímeros furtivos intrinsecamente desordenados e geneticamente modificados para entrega e métodos para uso dos mesmos

Info

Publication number
BR112018002342A2
BR112018002342A2 BR112018002342A BR112018002342A BR112018002342A2 BR 112018002342 A2 BR112018002342 A2 BR 112018002342A2 BR 112018002342 A BR112018002342 A BR 112018002342A BR 112018002342 A BR112018002342 A BR 112018002342A BR 112018002342 A2 BR112018002342 A2 BR 112018002342A2
Authority
BR
Brazil
Prior art keywords
delivery
methods
genetically modified
intrinsically disordered
stealth polymers
Prior art date
Application number
BR112018002342A
Other languages
English (en)
Inventor
Chilkoti Ashutosh
Bhattacharyya Jayanta
YOUSEFPOUR Parisa
Banskota Samagya
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of BR112018002342A2 publication Critical patent/BR112018002342A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)

Abstract

trata-se de conjugados que incluem um polipeptídeo e uma ou mais molé-culas de fármaco. o polipeptídeo inclui um ou mais motivos carregados e pode in-cluir, adicionalmente, um ou mais motivos não carregados. os conjugados podem ser usados para entregar, de maneira eficaz, a molécula de fármaco a um indivíduo.
BR112018002342A 2015-08-04 2016-08-04 polímeros furtivos intrinsecamente desordenados e geneticamente modificados para entrega e métodos para uso dos mesmos BR112018002342A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562200726P 2015-08-04 2015-08-04
PCT/US2016/045655 WO2017024182A1 (en) 2015-08-04 2016-08-04 Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same

Publications (1)

Publication Number Publication Date
BR112018002342A2 true BR112018002342A2 (pt) 2018-12-11

Family

ID=57943998

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018002342A BR112018002342A2 (pt) 2015-08-04 2016-08-04 polímeros furtivos intrinsecamente desordenados e geneticamente modificados para entrega e métodos para uso dos mesmos

Country Status (12)

Country Link
US (1) US11458205B2 (pt)
EP (1) EP3331557B1 (pt)
JP (1) JP6882782B2 (pt)
KR (1) KR20180033586A (pt)
CN (1) CN108463244B (pt)
AU (1) AU2016301391B2 (pt)
BR (1) BR112018002342A2 (pt)
CA (1) CA2994279A1 (pt)
EA (1) EA037478B1 (pt)
MX (1) MX2018001511A (pt)
WO (1) WO2017024182A1 (pt)
ZA (1) ZA201800939B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10385115B2 (en) 2015-03-26 2019-08-20 Duke University Fibronectin type III domain-based fusion proteins
BR112018002342A2 (pt) 2015-08-04 2018-12-11 Univ Duke polímeros furtivos intrinsecamente desordenados e geneticamente modificados para entrega e métodos para uso dos mesmos
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
US11467156B2 (en) 2016-06-01 2022-10-11 Duke University Nonfouling biosensors
RU2019110848A (ru) 2016-09-14 2020-10-15 Дьюк Юниверсити Наночастицы на основе триблочных полипептидов для доставки гидрофильных лекарственных средств
KR20190064600A (ko) 2016-09-23 2019-06-10 듀크 유니버시티 Lcst 거동을 갖는 비구조화된 비-반복적 폴리펩티드
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
US11554097B2 (en) 2017-05-15 2023-01-17 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
EP3658168A4 (en) 2017-06-30 2021-07-14 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-RESPONDING BIOPOLYMER NETWORKS
EP3829622A4 (en) 2018-08-02 2022-05-11 Duke University DUAL AGONIST FUSION PROTEINS
EP3864024A4 (en) * 2018-10-10 2022-07-06 University of Washington MIXED CHARGE PEPTIDE fusion products and bioconjugates
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
TW202214850A (zh) * 2020-06-09 2022-04-16 中央研究院 增強蛋白質表達和／或抑制其降解的方法和載體

Family Cites Families (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4976734A (en) 1985-10-31 1990-12-11 Uab Research Foundation Stimulation of chemotaxis by chemotactic peptides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5250516A (en) 1986-04-17 1993-10-05 Uab Research Foundation Bioelastomeric materials suitable for the protection of burn areas or the protection of wound repair sites from the occurrence of adhesions
US5336256A (en) 1986-04-17 1994-08-09 Uab Research Foundation Elastomeric polypeptides as vascular prosthetic materials
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5602244A (en) 1988-05-26 1997-02-11 Competitive Technologies, Inc. Polynucleotide phosphorodithioate compounds
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5362623A (en) 1991-06-14 1994-11-08 The John Hopkins University Sequence specific DNA binding by p53
DK0786469T3 (da) 1990-06-11 2006-07-10 Gilead Sciences Inc Nukleinsyreligander
US5545130A (en) 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
US5534408A (en) 1993-09-24 1996-07-09 University Of Massachusetts Medical Center 2-deoxystreptamine aminoglycoside inhibition of HIV RRE/Rev binding
JPH08502966A (ja) 1992-10-23 1996-04-02 ユニバーシティー・オブ・マサチューセッツ・メディカル・センター Ｒｎａ／リガンド結合の低分子抑制
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US6933366B2 (en) 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
US5763548A (en) 1995-03-31 1998-06-09 Carnegie-Mellon University (Co)polymers and a novel polymerization process based on atom (or group) transfer radical polymerization
US6541580B1 (en) 1995-03-31 2003-04-01 Carnegie Mellon University Atom or group transfer radical polymerization
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
AU740207B2 (en) 1997-02-06 2001-11-01 Novozymes A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
US6974669B2 (en) 2000-03-28 2005-12-13 Nanosphere, Inc. Bio-barcodes based on oligonucleotide-modified nanoparticles
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6120493A (en) 1998-01-27 2000-09-19 Genetronics, Inc. Method for the introduction of therapeutic agents utilizing an electroporation apparatus
US6208893B1 (en) 1998-01-27 2001-03-27 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6841617B2 (en) 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
US6296831B1 (en) 1998-04-10 2001-10-02 Battelle Memorial Institute Stimulus sensitive gel with radioisotope and methods of making
US7087244B2 (en) 2000-09-28 2006-08-08 Battelle Memorial Institute Thermogelling oligopeptide polymers
ATE275977T1 (de) 1998-04-13 2004-10-15 Massachusetts Inst Technology Kamm-polymere zur regelung der zelloberflächenwechselwirkung
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6302874B1 (en) 1998-07-13 2001-10-16 Genetronics, Inc. Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications
US6192270B1 (en) 1998-08-14 2001-02-20 Genetronics, Inc. Apparatus and method for the delivery of drugs and genes into tissue
US6150148A (en) 1998-10-21 2000-11-21 Genetronics, Inc. Electroporation apparatus for control of temperature during the process
US6413587B1 (en) 1999-03-02 2002-07-02 International Business Machines Corporation Method for forming polymer brush pattern on a substrate surface
AU3867400A (en) 1999-03-19 2000-10-09 Duke University Methods of using bioelastomers
US7163712B2 (en) 2000-03-03 2007-01-16 Duke University Microstamping activated polymer surfaces
US20050255554A1 (en) 2000-03-20 2005-11-17 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
US6852834B2 (en) 2000-03-20 2005-02-08 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
US7351376B1 (en) 2000-06-05 2008-04-01 California Institute Of Technology Integrated active flux microfluidic devices and methods
US6660247B1 (en) 2000-06-23 2003-12-09 Battelle Memorial Institute Multiple stimulus reversible hydrogels
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
EP1455816A4 (en) 2000-10-19 2007-03-28 Epimmune Inc HLA CLASS I AND II BINDING PEPTIDES AND THEIR USE
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US6528287B2 (en) 2001-02-13 2003-03-04 Nestor D. Tomycz Recombinant human serum transferrins containing peptides for inducing apoptosis in HIV-1 infected cells
WO2002081372A2 (en) 2001-04-06 2002-10-17 Carnegie Mellon University A process for the preparation of nanostructured materials
WO2002081729A2 (en) 2001-04-06 2002-10-17 California Institute Of Technology Nucleic acid amplification utilizing microfluidic devices
SG157961A1 (en) 2001-05-25 2010-01-29 Univ Duke Modulators of pharmacological agents
US20070117173A1 (en) 2001-09-05 2007-05-24 Levison Peter R Stable storage of proteins
US7179785B2 (en) 2001-11-21 2007-02-20 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same
WO2003048295A1 (en) 2001-11-30 2003-06-12 Fluidigm Corporation Microfluidic device and methods of using same
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US20040101852A1 (en) 2002-11-21 2004-05-27 Isis Pharmaceuticals Inc. Modulation of CGG triplet repeat binding protein 1 expression
EP1504033A2 (en) 2002-05-03 2005-02-09 Millenium Biologix Inc. Connective tissue stimulating peptides
CA2525994C (en) 2002-06-24 2012-10-16 Tufts University Silk biomaterials and methods of use thereof
EP2277551B1 (en) 2002-09-06 2013-05-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US6918284B2 (en) 2003-03-24 2005-07-19 The United States Of America As Represented By The Secretary Of The Navy Interconnected networks of single-walled carbon nanotubes
AU2003237792A1 (en) 2003-04-01 2004-11-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP5019511B2 (ja) 2003-09-17 2012-09-05 サイトリ セラピューティクス インコーポレイテッド 抹消血管疾患およびそれに関連する障害の治療において新生細胞を利用する方法
WO2005062977A2 (en) 2003-12-23 2005-07-14 The Regents Of The University Of California Prostate cancer specific internalizing human antibodies
ES2494940T3 (es) 2004-04-22 2014-09-16 Regado Biosciences, Inc. Moduladores de factores de coagulación mejorados
WO2006004778A2 (en) 2004-06-30 2006-01-12 Dentsply International Inc. Implant with a biofunctionalized surface and method for its production
US7884185B2 (en) 2004-07-28 2011-02-08 University Of Delaware Hydrogels and uses thereof
US7812051B2 (en) 2004-08-11 2010-10-12 Arqule, Inc. Pharmaceutical compositions of β-lapachone and β-lapachone analogs with improved tumor targeting potential
WO2006110292A2 (en) 2005-03-25 2006-10-19 The Regents Of The University Of California Temperature-triggered immobilization and purification of antibodies
KR101762424B1 (ko) 2005-05-09 2017-07-28 테라노스, 인코포레이티드 현장진료 유체 시스템 및 그 용도
CN101500606B (zh) * 2005-06-24 2013-12-04 杜克大学 基于热反应生物聚合物的直接药物送递***
WO2007024393A2 (en) 2005-08-25 2007-03-01 University Of Washington Super-low fouling sulfobetaine and carboxybetaine materials and related methods
WO2007035527A2 (en) 2005-09-15 2007-03-29 Duke University Non-fouling polymeric surface modification and signal amplification method for biomolecular detection
WO2007073486A2 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US7709227B2 (en) 2006-01-04 2010-05-04 Phasebio Pharmaceuticals, Inc. Multimeric ELP fusion constructs
US8841414B1 (en) 2006-01-27 2014-09-23 University Of Mississippi Medical Center Targeted delivery of therapeutic peptides by thermally responsive biopolymers
WO2007108013A2 (en) 2006-03-22 2007-09-27 National Institute Of Immunology Novel bioconjugates as therapeutic agent and synthesis thereof
WO2007134245A2 (en) 2006-05-12 2007-11-22 Wisconsin Alumni Research Foundation Elastin-like polymer delivery vehicles
CA2947349A1 (en) 2006-06-13 2007-12-21 Helix Biomedix Inc. Peptide fragments for inducing synthesis of extracellular matrix proteins
EP2032255B1 (en) 2006-06-23 2010-11-10 STMicroelectronics Srl Assembly of a microfluidic device for analysis of biological material
AU2007265628B2 (en) 2006-06-23 2012-12-06 Perkinelmer Health Sciences, Inc. Methods and devices for microfluidic point-of-care immunoassays
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
CN103230598A (zh) * 2006-09-06 2013-08-07 费斯生物制药公司 融合肽治疗组合物
WO2008033847A2 (en) 2006-09-11 2008-03-20 Emory University Modified protein polymers
US8101403B2 (en) 2006-10-04 2012-01-24 University Of Washington Method and device for rapid parallel microfluidic molecular affinity assays
WO2008055931A1 (de) 2006-11-08 2008-05-15 Basf Se Verwendung von natürlichen, rekombinanten und synthetischen resilinen in der kosmetik
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
CA2682580A1 (en) 2007-03-30 2008-10-09 Duke University A method of modulating the activity of a nucleic acid molecule
CN101765608B (zh) 2007-07-31 2015-03-11 阿菲博迪公司 新白蛋白结合组合物、方法及应用
US8366652B2 (en) 2007-08-17 2013-02-05 The Invention Science Fund I, Llc Systems, devices, and methods including infection-fighting and monitoring shunts
WO2009026233A2 (en) 2007-08-17 2009-02-26 Northwestern University Self assembling peptide systems and methods
ES2319061B1 (es) 2007-09-11 2010-02-10 Biomedal, S.L. Metodo de conservacion de peptidos o proteinas.
EP2657699B1 (en) 2007-10-02 2017-03-22 Theranos, Inc. Modular point-of-care devices and uses thereof
US20110207673A1 (en) 2007-11-20 2011-08-25 Ashutosh Chilkoti Methods and compositions for modulating drug-polymer architecture, pharmacokinetics and biodistribution
DE102007057802B3 (de) 2007-11-30 2009-06-10 Geneart Ag Steganographische Einbettung von Informationen in kodierenden Genen
AU2008338530A1 (en) 2007-12-14 2009-06-25 Minitube Of America, Inc. Gender-specific separation of sperm cells and embryos
US8796184B2 (en) 2008-03-28 2014-08-05 Sentilus, Inc. Detection assay devices and methods of making and using the same
EP2307038A4 (en) 2008-06-27 2013-03-27 Univ Duke THERAPEUTIC AGENTS COMPRISING ELASTINE-LIKE PEPTIDES
KR101026468B1 (ko) 2008-09-10 2011-04-01 한국전자통신연구원 생분자 검출 장치 및 검출 방법
WO2010054699A1 (en) 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
TW201029668A (en) 2008-11-17 2010-08-16 Enzon Pharmaceuticals Inc Releasable conjugates for nucleic acids delivery systems
CN106905429A (zh) 2008-12-05 2017-06-30 阿布拉西斯生物科学有限责任公司 结合SPARC的scFv
GB0913775D0 (en) 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
WO2010096422A1 (en) 2009-02-17 2010-08-26 Duke University Biomolecule polymer conjugates and methods for making the same
WO2010142665A1 (en) 2009-06-11 2010-12-16 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
USPP21973P3 (en) 2009-06-23 2011-06-14 Cellfor Inc. Loblolly pine tree named ‘CF LP1-7696’
EP2287221A1 (en) 2009-07-16 2011-02-23 Stichting Katholieke Universiteit meer in het bijzonder Radboud Universiteit Nijmegen Method for the preparation of high molecular weight oligo(alkylene glycol) functionalized polyisocyanopeptides
CA2772551A1 (en) * 2009-08-26 2011-03-03 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP2481754B1 (en) 2009-09-22 2014-06-18 Shanghai Yijie Biotechnology Co., Ltd Specific binding proteins and uses thereof
US8602051B2 (en) 2009-12-10 2013-12-10 Brent W. Proper Trap-primer system for floor drains
WO2011100700A2 (en) 2010-02-12 2011-08-18 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
EP2550529B1 (en) 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
EP2552967A4 (en) * 2010-04-02 2014-10-08 Amunix Operating Inc BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
JP2011220803A (ja) 2010-04-08 2011-11-04 Mitsumi Electric Co Ltd 電界効果トランジスタ素子を具備するバイオセンサ
JP2013523179A (ja) 2010-04-13 2013-06-17 メディミューン，エルエルシー フィブロネクチンタイプｉｉｉドメインに基づく多量体足場
EP3305192B1 (en) 2010-05-17 2019-10-09 Sentilus Holdco, LLC Detection devices and related methods of use
EP2418284A1 (en) 2010-08-13 2012-02-15 ERA Biotech, S.A. Protein body-inducing polypeptide sequences
WO2011155565A1 (ja) 2010-06-10 2011-12-15 国立大学法人九州工業大学 可逆的な性質を示す温度応答性シートとそれを用いた細胞シートの製造方法
TW201217783A (en) 2010-09-15 2012-05-01 Mbio Diagnostics Inc System and method for detecting multiple molecules in one assay
US8470967B2 (en) 2010-09-24 2013-06-25 Duke University Phase transition biopolymers and methods of use
AU2011323508B2 (en) 2010-11-01 2017-04-27 Peptimed, Inc. Compositions of a peptide targeting system for treating cancer
WO2012162426A1 (en) 2011-05-23 2012-11-29 The University Of North Carolina At Chapel Hill Methods and compositions for heptameric targeting ligands
KR101357117B1 (ko) 2011-06-28 2014-02-06 비앤엘델리팜 주식회사 폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
US9775803B2 (en) 2011-10-19 2017-10-03 Samsung Electronics Co., Ltd. Liposome comprising elastin-like polypeptide and tumor cell targeting material and use thereof
WO2013059805A1 (en) 2011-10-21 2013-04-25 Decimadx, Llc Point-of care immunoassay for quantitative small analyte detection
WO2013065009A1 (en) 2011-11-01 2013-05-10 National Institute Of Immunology A sortase-click reaction suite for synthesis of multivalent dendrimeric protein assembly
AU2012346058A1 (en) 2011-11-28 2014-06-12 Phasebio Pharmaceuticals, Inc. Therapeutic agents comprising insulin amino acid sequences
WO2013106715A1 (en) 2012-01-13 2013-07-18 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
EP2623097B1 (en) 2012-02-01 2015-07-15 Samsung Electronics Co., Ltd Solid lipid nanoparticles including elastin-like polypeptides and use thereof
BR112015004734A2 (pt) 2012-09-07 2017-11-21 Sanofi Sa proteínas de fusão para tratar uma síndrome metabólica
AU2014212640B2 (en) 2013-01-30 2017-10-19 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
JP2014156428A (ja) 2013-02-15 2014-08-28 Univ Of Tokyo 抗体結合タンパク質
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
KR102109188B1 (ko) 2013-04-01 2020-05-11 삼성전자주식회사 양이온성 지질을 포함하는 온도민감성 리포좀 및 그의 용도
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US9592303B2 (en) 2013-05-30 2017-03-14 Duke University Enzyme-catalyzed synthesis of site-specific and stoichiometric biomolecule-polymer conjugates
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
WO2015011231A1 (en) 2013-07-25 2015-01-29 Universitat Rovira I Virgili Method and system for the multiplex identification of analytes in fluids
US9777041B2 (en) 2013-09-09 2017-10-03 New York University Protein nanofibers from self-assembling pentamers
CA2926215A1 (en) 2013-10-06 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified pseudomonas exotoxin a
CN105848649B (zh) 2013-11-01 2019-08-02 耶鲁大学 用于免疫疗法的模块化粒子
US10449267B2 (en) 2013-11-13 2019-10-22 Massachusetts Institute Of Technology Self-assembling underwater adhesives
US11268127B2 (en) 2014-02-04 2022-03-08 Duke University Systems and devices for protease detection based on engineered polymers and biopolymers and methods of use
WO2015120287A2 (en) 2014-02-06 2015-08-13 Yale University Compositions and methods of use thereof for making polypeptides with many instances of nonstandard amino acids
WO2015130846A2 (en) 2014-02-25 2015-09-03 Duke University Compositions and methods for the site-specific modification of polypeptides
US10131690B2 (en) 2014-04-25 2018-11-20 Phi Pharma Sa C6S specific transporter molecules
BR102014014502B1 (pt) 2014-06-13 2020-09-15 Ouro Fino Saúde Animal Ltda Vetor de expressão
CN104877127B (zh) 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质
CN104725628B (zh) 2014-10-01 2018-04-17 厦门赛诺邦格生物科技股份有限公司 一种含可降解基团的单一官能化支化聚乙二醇、制备方法及其生物相关物质
WO2016065300A1 (en) 2014-10-24 2016-04-28 Eshoo Mark W Microfluidic cartridge
US11053504B2 (en) 2014-10-24 2021-07-06 The University Of Chicago Heat-inducible self-assembling protein domains
WO2016090103A1 (en) 2014-12-04 2016-06-09 The Trustees Of Columbia University In The City Of New York Biodegradable thermo-responsive polymers and uses thereof
US9702847B2 (en) 2014-12-30 2017-07-11 Avails Medical, Inc. Systems and methods for detecting a substance in bodily fluid
US9804170B2 (en) 2015-02-09 2017-10-31 Bristol-Myers Squibb Company Antibodies to polyethylene glycol
US9956300B2 (en) 2015-03-18 2018-05-01 Duke Univerity Hydrogels formed from polypeptide micelles and methods of use thereof
US10385115B2 (en) 2015-03-26 2019-08-20 Duke University Fibronectin type III domain-based fusion proteins
US10064954B2 (en) 2015-06-23 2018-09-04 Nian Wu Polymer-cyclodextrin-lipid conjugates
AU2016287499B2 (en) 2015-06-29 2022-08-04 Caris Science, Inc. Therapeutic oligonucleotides
US11169150B2 (en) 2015-07-20 2021-11-09 Sentilus Holdco LLC Chips, detectors, and methods of making and using the same
BR112018002342A2 (pt) 2015-08-04 2018-12-11 Univ Duke polímeros furtivos intrinsecamente desordenados e geneticamente modificados para entrega e métodos para uso dos mesmos
WO2017027384A1 (en) 2015-08-07 2017-02-16 Poc Medical Systems, Inc. Microfluidic devices and methods of use thereof
US9678037B2 (en) 2015-10-08 2017-06-13 The Regents Of The University Of Michigan Two-dimensional material-based field-effect transistor sensors
US10688175B2 (en) 2015-10-13 2020-06-23 Daniel C. Carter NSP10 self-assembling fusion proteins for vaccines, therapeutics, diagnostics and other nanomaterial applications
WO2017075531A1 (en) 2015-10-28 2017-05-04 Acuitas Therapeutics, Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017083423A1 (en) 2015-11-10 2017-05-18 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating aav infection
US9496239B1 (en) 2015-12-11 2016-11-15 International Business Machines Corporation Nitride-enriched oxide-to-oxide 3D wafer bonding
WO2017112826A2 (en) 2015-12-21 2017-06-29 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
WO2017171001A1 (ja) 2016-03-31 2017-10-05 味の素株式会社 フィブロイン様タンパク質改変体および細胞培養方法
ES2909074T3 (es) 2016-05-06 2022-05-05 Phasebio Pharmaceuticals Inc Proteínas de fusión ELP para liberación controlada y sostenida
JP7289265B2 (ja) 2016-10-26 2023-06-09 キュアバック エスイー 脂質ナノ粒子ｍＲＮＡワクチン
AU2017382038A1 (en) 2016-12-22 2019-08-08 Sanofi FGF21 compound / GLP-1R agonist combinations with optimized activity ratio
WO2018126084A1 (en) 2016-12-30 2018-07-05 Phaserx, Inc. Branched peg molecules and related compositions and methods
US20190359983A1 (en) 2017-02-02 2019-11-28 Caris Science, Inc. Targeted oligonucleotides
US11554097B2 (en) 2017-05-15 2023-01-17 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
AU2018283184B2 (en) 2017-06-14 2021-08-19 EMULATE, Inc. Effects of space travel on human brain cells
EP3658168A4 (en) 2017-06-30 2021-07-14 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-RESPONDING BIOPOLYMER NETWORKS
US11235324B2 (en) 2017-11-22 2022-02-01 Hewlett-Packard Development Company, L.P. Temperature-cycling microfluidic devices
WO2019147954A1 (en) 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
US20190292549A1 (en) 2018-03-22 2019-09-26 Northeastern University Poly(ethylene glycol) brushes for efficient rna delivery
US20210268465A1 (en) 2018-08-17 2021-09-02 The Regents Of The University Of California Particle-containing droplet systems with monodisperse fluid volumes
WO2020160472A1 (en) 2019-02-01 2020-08-06 Sentilus Holdco, Llc High-sensitivity assay

Also Published As

Publication number Publication date
JP6882782B2 (ja) 2021-06-02
EA201890417A1 (ru) 2018-08-31
JP2018525989A (ja) 2018-09-13
WO2017024182A1 (en) 2017-02-09
EP3331557A1 (en) 2018-06-13
KR20180033586A (ko) 2018-04-03
EP3331557A4 (en) 2019-03-13
AU2016301391A1 (en) 2018-02-22
CN108463244A (zh) 2018-08-28
AU2016301391B2 (en) 2022-07-28
US20180228908A1 (en) 2018-08-16
CN108463244B (zh) 2022-05-27
ZA201800939B (en) 2019-05-29
EA037478B1 (ru) 2021-04-01
EP3331557B1 (en) 2021-04-07
CA2994279A1 (en) 2017-02-09
MX2018001511A (es) 2018-08-01
US11458205B2 (en) 2022-10-04

Similar Documents

Publication Publication Date Title
BR112018002342A2 (pt) polímeros furtivos intrinsecamente desordenados e geneticamente modificados para entrega e métodos para uso dos mesmos
CY1123571T1 (el) Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα
BR112018010018A2 (pt) moduladores de ror-gama
BR112017007543A2 (pt) peptídeos com propriedades anti-inflamatórias
NI201800038S (es) Dispositivo de administración de medicamento intranasal
BR112017016503A2 (pt) conjugado de fármaco de citotoxicidade-ligante, método de preparação para o mesmo, e aplicação para o mesmo
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
EA033345B1 (ru) ТРИЦИКЛИЧЕСКИЕ СУЛЬФОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ
CY1123720T1 (el) Συνθεσεις ενος πολυορθοεστερα και ενος εκδοχου οργανικου οξεος
BR112018077541A2 (pt) formulações orais gastrorretentivas e usos das mesmas
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CY1123844T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
EA201700019A1 (ru) Высокочистый оритаванцин и способ его получения
CL2016000148A1 (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
BR112017028552A2 (pt) partículas e conjugados direcionados e formulações dos mesmos
BR112017008867A2 (pt) inibidores de proteína quinases
EA201991287A1 (ru) Твердые фармацевтические композиции на основе тикагрелора для перорального применения
BR112019006075A2 (pt) medicamento
BR112017020404A2 (pt) medicamento
BR112017016388A2 (pt) cenicriviroc para o tratamento da fibrose
BR112017001888A2 (pt) formulações biológicas para instilação intravesical
DK3453390T3 (da) Farmaceutisk sammensætning indeholdende polymeriseret lægemiddel
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]